Shexiang Baoxin Wan: A 2001 Modern Joint Venture Built on a Song-Dynasty Formula Ancestor

Disclaimer: This page is for historical and cultural education only and is not medical advice. References to traditional use describe what historical sources record or what is traditionally believed — not a claim that any product treats, cures, or prevents any disease. These statements have not been evaluated by the U.S. Food and Drug Administration or any other regulator. Consult a qualified physician with any health questions.

Shexiang Baoxin Wan (麝香保心丸) is made by Shanghai Hutchison Pharmaceuticals, a company formed in August 2001 as a joint venture between Hutchison Whampoa China and the Shanghai Pharmaceutical Materials company. Unlike every other house on this site, it is not a centuries-old time-honored apothecary carried forward under a modern corporate shell — it is, by company age, a modern enterprise. This page keeps that distinction explicit throughout, rather than folding it into a centuries-old-house narrative it doesn't fit.

The real history here: a 1970s pharmacological redesign

The product's formula draws on a distant ancestor, the Song-dynasty formula Suhexiang Wan, but the product sold today is not a direct centuries-old recipe. In the 1970s, a project led by the Shanghai Health Bureau, with a team from Huashan Hospital headed by Dai Ruihong, pharmacologically redesigned the ancestor formula — removing components with nephrotoxic effects and mercury content. This modern redesign, not a continuous centuries-old lineage, is this brand's genuinely notable historical chapter. It was finalized in the early 1980s.

What "time-honored" means for this brand specifically

In 2023, the "Shangyao" trademark under which this product is sold received Shanghai Time-Honored Brand status — a municipal-level designation. This site did not find evidence of the national-level China Time-Honored Brand recognition that several other houses on this site hold, nor of any intangible-cultural-heritage listing for this product. This page states the Shanghai-level designation only, and does not use the "China Time-Honored Brand" term for this house.

Ownership: a "Hutchison" name with a changed present-day structure

Since 2025, Shanghai Pharmaceuticals (601607) has been acquiring shares from Hutchison China MediTech, raising its stake in the joint venture to a controlling roughly 60%, with Hutchison China MediTech's remaining stake at around 5%. The Hutchison name in the company's own name reflects its 2001 founding history; today's ownership is majority domestic. This page describes the Hutchison Whampoa connection as historical rather than as a description of current control.

Shexiang Baoxin Wan's formula and manufacturing process are widely reported to hold protected, state-secret status in China, on evidence weaker than for some of the other houses on this site — this page uses "widely reported" rather than a more confident phrasing to reflect that.

This site's strongest international academic visibility

Uniquely among the houses covered here, Shexiang Baoxin Wan has a documented international academic presence: its international generic name, "MUSKARDIA," appears in multiple peer-reviewed pharmacology and cardiology papers, and the product has a registered clinical trial listed on ClinicalTrials.gov. This is a real, independently verifiable form of international visibility, distinct from the sales and retail evidence tracked for other houses on this site.

One caveat is worth stating plainly alongside it: the flagship randomized controlled trial behind this visibility — more than 2,600 patients across 97 hospitals — was conducted entirely at sites within China. That academic visibility is not evidence of overseas clinical enrollment.

Overseas retail: the thinnest footprint on this site, honestly stated

Of the houses covered on this site, this is the only one where this round's research found no formal pharmacy or retail-chain presence anywhere overseas. The one market with any retail trace at all is Indonesia, where the product appears through informal, individual seller listings on an e-commerce platform — not a formal pharmacy presence. Beyond that, some overseas Chinese community retail channels in North America carry the product informally. No comparable retail trace was found in Vietnam, Thailand, or the Philippines in this round of research, and this site did not confirm a presence in Hong Kong or Macau pharmacy chains either.

That combination — a modern international corporate origin, this site's strongest documented academic and clinical visibility, and its thinnest overseas retail footprint — is a real contrast worth stating plainly rather than smoothing over.